Selected research
Industry Research
Pan-cancer Genomic Profiling Industry Research Report 2026
Market perspective
The global Pan-cancer Genomic Profiling market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Pan-cancer Genomic Profiling market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Pan-cancer Genomic Profiling market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Pan-cancer Genomic Profiling market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Pan-cancer Genomic Profiling include Tempus AI, Labcorp, NeoGenomics, Exact Sciences, Personalis, Illumina, Thermo Fisher Scientific, QIAGEN and Agilent Technologies, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Pan-cancer Genomic Profiling market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Pan-cancer Genomic Profiling.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pan-cancer Genomic Profiling Market by Company
Tempus AI
Labcorp
NeoGenomics
Exact Sciences
Personalis
Illumina
Thermo Fisher Scientific
QIAGEN
Agilent Technologies
SOPHiA GENETICS
Sysmex
Burning Rock Biotech
Genetron Health
Geneseeq
BGI Genomics
Amoy Diagnostics
Roche
Guardant Health
Caris Life Sciences
Pan-cancer Genomic Profiling Segment by Type
Tissue-based Profiling
Liquid Biopsy Profiling
Other
Pan-cancer Genomic Profiling Segment by Application
Hospitals and Cancer Centers
Independent Clinical Laboratories
Pharmaceutical and Biotechnology Companies
Other
Pan-cancer Genomic Profiling Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pan-cancer Genomic Profiling market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pan-cancer Genomic Profiling and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pan-cancer Genomic Profiling.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Pan-cancer Genomic Profiling companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tissue-based Profiling
- Liquid Biopsy Profiling
- Other
Applications
- Hospitals and Cancer Centers
- Independent Clinical Laboratories
- Pharmaceutical and Biotechnology Companies
- Other
Companies covered
- Tempus AI
- Labcorp
- NeoGenomics
- Exact Sciences
- Personalis
- Illumina
- Thermo Fisher Scientific
- QIAGEN
- Agilent Technologies
- SOPHiA GENETICS
- Sysmex
- Burning Rock Biotech
- Genetron Health
- Geneseeq
- BGI Genomics
- Amoy Diagnostics
- Roche
- Guardant Health
- Caris Life Sciences
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Pan-cancer Genomic Profiling by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Tissue-based Profiling
- 2.2.3 Liquid Biopsy Profiling
- 2.2.4 Other
- 2.3 Pan-cancer Genomic Profiling by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospitals and Cancer Centers
- 2.3.3 Independent Clinical Laboratories
- 2.3.4 Pharmaceutical and Biotechnology Companies
- 2.3.5 Other
- 2.4 Assumptions and Limitations
3 Pan-cancer Genomic Profiling Breakdown Data by Type
- 3.1 Global Pan-cancer Genomic Profiling Historic Market Size by Type (2021-2026)
- 3.2 Global Pan-cancer Genomic Profiling Forecasted Market Size by Type (2027-2032)
4 Pan-cancer Genomic Profiling Breakdown Data by Application
- 4.1 Global Pan-cancer Genomic Profiling Historic Market Size by Application (2021-2026)
- 4.2 Global Pan-cancer Genomic Profiling Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Pan-cancer Genomic Profiling Market Perspective (2021-2032)
- 5.2 Global Pan-cancer Genomic Profiling Growth Trends by Region
- 5.2.1 Global Pan-cancer Genomic Profiling Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Pan-cancer Genomic Profiling Historic Market Size by Region (2021-2026)
- 5.2.3 Pan-cancer Genomic Profiling Forecasted Market Size by Region (2027-2032)
- 5.3 Pan-cancer Genomic Profiling Market Dynamics
- 5.3.1 Pan-cancer Genomic Profiling Industry Trends
- 5.3.2 Pan-cancer Genomic Profiling Market Drivers
- 5.3.3 Pan-cancer Genomic Profiling Market Challenges
- 5.3.4 Pan-cancer Genomic Profiling Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Pan-cancer Genomic Profiling Players by Revenue
- 6.1.1 Global Top Pan-cancer Genomic Profiling Players by Revenue (2021-2026)
- 6.1.2 Global Pan-cancer Genomic Profiling Revenue Market Share by Players (2021-2026)
- 6.2 Global Pan-cancer Genomic Profiling Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Pan-cancer Genomic Profiling Head Office and Area Served
- 6.4 Global Pan-cancer Genomic Profiling Players, Product Type & Application
- 6.5 Global Pan-cancer Genomic Profiling Manufacturers Established Date
- 6.6 Global Pan-cancer Genomic Profiling Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Pan-cancer Genomic Profiling Market Size (2021-2032)
- 7.2 North America Pan-cancer Genomic Profiling Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Pan-cancer Genomic Profiling Market Size by Country (2021-2026)
- 7.4 North America Pan-cancer Genomic Profiling Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Pan-cancer Genomic Profiling Market Size (2021-2032)
- 8.2 Europe Pan-cancer Genomic Profiling Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Pan-cancer Genomic Profiling Market Size by Country (2021-2026)
- 8.4 Europe Pan-cancer Genomic Profiling Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Pan-cancer Genomic Profiling Market Size (2021-2032)
- 9.2 Asia-Pacific Pan-cancer Genomic Profiling Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Pan-cancer Genomic Profiling Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Pan-cancer Genomic Profiling Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Pan-cancer Genomic Profiling Market Size (2021-2032)
- 10.2 South America Pan-cancer Genomic Profiling Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Pan-cancer Genomic Profiling Market Size by Country (2021-2026)
- 10.4 South America Pan-cancer Genomic Profiling Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Pan-cancer Genomic Profiling Market Size (2021-2032)
- 11.2 Middle East & Africa Pan-cancer Genomic Profiling Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Pan-cancer Genomic Profiling Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Pan-cancer Genomic Profiling Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Tempus AI
- 12.1.1 Tempus AI Company Information
- 12.1.2 Tempus AI Business Overview
- 12.1.3 Tempus AI Revenue in Pan-cancer Genomic Profiling Business (2021-2026)
- 12.1.4 Tempus AI Pan-cancer Genomic Profiling Product Portfolio
- 12.1.5 Tempus AI Recent Developments
- 12.2 Labcorp
- 12.2.1 Labcorp Company Information
- 12.2.2 Labcorp Business Overview
- 12.2.3 Labcorp Revenue in Pan-cancer Genomic Profiling Business (2021-2026)
- 12.2.4 Labcorp Pan-cancer Genomic Profiling Product Portfolio
- 12.2.5 Labcorp Recent Developments
- 12.3 NeoGenomics
- 12.3.1 NeoGenomics Company Information
- 12.3.2 NeoGenomics Business Overview
- 12.3.3 NeoGenomics Revenue in Pan-cancer Genomic Profiling Business (2021-2026)
- 12.3.4 NeoGenomics Pan-cancer Genomic Profiling Product Portfolio
- 12.3.5 NeoGenomics Recent Developments
- 12.4 Exact Sciences
- 12.4.1 Exact Sciences Company Information
- 12.4.2 Exact Sciences Business Overview
- 12.4.3 Exact Sciences Revenue in Pan-cancer Genomic Profiling Business (2021-2026)
- 12.4.4 Exact Sciences Pan-cancer Genomic Profiling Product Portfolio
- 12.4.5 Exact Sciences Recent Developments
- 12.5 Personalis
- 12.5.1 Personalis Company Information
- 12.5.2 Personalis Business Overview
- 12.5.3 Personalis Revenue in Pan-cancer Genomic Profiling Business (2021-2026)
- 12.5.4 Personalis Pan-cancer Genomic Profiling Product Portfolio
- 12.5.5 Personalis Recent Developments
- 12.6 Illumina
- 12.6.1 Illumina Company Information
- 12.6.2 Illumina Business Overview
- 12.6.3 Illumina Revenue in Pan-cancer Genomic Profiling Business (2021-2026)
- 12.6.4 Illumina Pan-cancer Genomic Profiling Product Portfolio
- 12.6.5 Illumina Recent Developments
- 12.7 Thermo Fisher Scientific
- 12.7.1 Thermo Fisher Scientific Company Information
- 12.7.2 Thermo Fisher Scientific Business Overview
- 12.7.3 Thermo Fisher Scientific Revenue in Pan-cancer Genomic Profiling Business (2021-2026)
- 12.7.4 Thermo Fisher Scientific Pan-cancer Genomic Profiling Product Portfolio
- 12.7.5 Thermo Fisher Scientific Recent Developments
- 12.8 QIAGEN
- 12.8.1 QIAGEN Company Information
- 12.8.2 QIAGEN Business Overview
- 12.8.3 QIAGEN Revenue in Pan-cancer Genomic Profiling Business (2021-2026)
- 12.8.4 QIAGEN Pan-cancer Genomic Profiling Product Portfolio
- 12.8.5 QIAGEN Recent Developments
- 12.9 Agilent Technologies
- 12.9.1 Agilent Technologies Company Information
- 12.9.2 Agilent Technologies Business Overview
- 12.9.3 Agilent Technologies Revenue in Pan-cancer Genomic Profiling Business (2021-2026)
- 12.9.4 Agilent Technologies Pan-cancer Genomic Profiling Product Portfolio
- 12.9.5 Agilent Technologies Recent Developments
- 12.10 SOPHiA GENETICS
- 12.10.1 SOPHiA GENETICS Company Information
- 12.10.2 SOPHiA GENETICS Business Overview
- 12.10.3 SOPHiA GENETICS Revenue in Pan-cancer Genomic Profiling Business (2021-2026)
- 12.10.4 SOPHiA GENETICS Pan-cancer Genomic Profiling Product Portfolio
- 12.10.5 SOPHiA GENETICS Recent Developments
- 12.11 Sysmex
- 12.11.1 Sysmex Company Information
- 12.11.2 Sysmex Business Overview
- 12.11.3 Sysmex Revenue in Pan-cancer Genomic Profiling Business (2021-2026)
- 12.11.4 Sysmex Pan-cancer Genomic Profiling Product Portfolio
- 12.11.5 Sysmex Recent Developments
- 12.12 Burning Rock Biotech
- 12.12.1 Burning Rock Biotech Company Information
- 12.12.2 Burning Rock Biotech Business Overview
- 12.12.3 Burning Rock Biotech Revenue in Pan-cancer Genomic Profiling Business (2021-2026)
- 12.12.4 Burning Rock Biotech Pan-cancer Genomic Profiling Product Portfolio
- 12.12.5 Burning Rock Biotech Recent Developments
- 12.13 Genetron Health
- 12.13.1 Genetron Health Company Information
- 12.13.2 Genetron Health Business Overview
- 12.13.3 Genetron Health Revenue in Pan-cancer Genomic Profiling Business (2021-2026)
- 12.13.4 Genetron Health Pan-cancer Genomic Profiling Product Portfolio
- 12.13.5 Genetron Health Recent Developments
- 12.14 Geneseeq
- 12.14.1 Geneseeq Company Information
- 12.14.2 Geneseeq Business Overview
- 12.14.3 Geneseeq Revenue in Pan-cancer Genomic Profiling Business (2021-2026)
- 12.14.4 Geneseeq Pan-cancer Genomic Profiling Product Portfolio
- 12.14.5 Geneseeq Recent Developments
- 12.15 BGI Genomics
- 12.15.1 BGI Genomics Company Information
- 12.15.2 BGI Genomics Business Overview
- 12.15.3 BGI Genomics Revenue in Pan-cancer Genomic Profiling Business (2021-2026)
- 12.15.4 BGI Genomics Pan-cancer Genomic Profiling Product Portfolio
- 12.15.5 BGI Genomics Recent Developments
- 12.16 Amoy Diagnostics
- 12.16.1 Amoy Diagnostics Company Information
- 12.16.2 Amoy Diagnostics Business Overview
- 12.16.3 Amoy Diagnostics Revenue in Pan-cancer Genomic Profiling Business (2021-2026)
- 12.16.4 Amoy Diagnostics Pan-cancer Genomic Profiling Product Portfolio
- 12.16.5 Amoy Diagnostics Recent Developments
- 12.17 Roche
- 12.17.1 Roche Company Information
- 12.17.2 Roche Business Overview
- 12.17.3 Roche Revenue in Pan-cancer Genomic Profiling Business (2021-2026)
- 12.17.4 Roche Pan-cancer Genomic Profiling Product Portfolio
- 12.17.5 Roche Recent Developments
- 12.18 Guardant Health
- 12.18.1 Guardant Health Company Information
- 12.18.2 Guardant Health Business Overview
- 12.18.3 Guardant Health Revenue in Pan-cancer Genomic Profiling Business (2021-2026)
- 12.18.4 Guardant Health Pan-cancer Genomic Profiling Product Portfolio
- 12.18.5 Guardant Health Recent Developments
- 12.19 Caris Life Sciences
- 12.19.1 Caris Life Sciences Company Information
- 12.19.2 Caris Life Sciences Business Overview
- 12.19.3 Caris Life Sciences Revenue in Pan-cancer Genomic Profiling Business (2021-2026)
- 12.19.4 Caris Life Sciences Pan-cancer Genomic Profiling Product Portfolio
- 12.19.5 Caris Life Sciences Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst